Retromer Therapeutics

Year Invested/Status: 2020/Active

Motivation: Despite multiple attempts to curtail progression of neurodegenerative diseases, few safe & efficacious therapeutics have come to market, underscoring the importance of accelerating novel approaches to a disease modifying therapeutic.

Lead Program(s): Retromer Therapeutics is pioneering a new class of therapeutics to treat neurodegenerative diseases by restoring the function of the endolysosmal trafficking system with preclinical programs in neurodegenerative diseases.

Pre-Clinical

Phase 1

Phase 2

Phase 3

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES